Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition …
Therachon
Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia
BASEL, Switzerland, February 14, 2018 – Therachon AG, a biotechnology company focused on rare genetic diseases, today …
Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia
BASEL, Switzerland — June 20, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced …